KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Deferred Revenue (2016 - 2026)

Biocryst Pharmaceuticals filings provide 14 years of Current Deferred Revenue readings, the most recent being $522000.0 for Q3 2023.

  • On a quarterly basis, Current Deferred Revenue fell 66.41% to $522000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $522000.0, a 66.41% decrease, with the full-year FY2022 number at $1.2 million, down 13.86% from a year prior.
  • Current Deferred Revenue hit $522000.0 in Q3 2023 for Biocryst Pharmaceuticals, down from $1.8 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.1 million in Q4 2019 to a low of $150000.0 in Q4 2020.
  • Median Current Deferred Revenue over the past 5 years was $834500.0 (2020), compared with a mean of $926777.8.
  • The widest YoY moves for Current Deferred Revenue: up 859.28% in 2019, down 96.97% in 2019.
  • Biocryst Pharmaceuticals' Current Deferred Revenue stood at $2.1 million in 2019, then plummeted by 92.92% to $150000.0 in 2020, then soared by 847.33% to $1.4 million in 2021, then fell by 13.86% to $1.2 million in 2022, then tumbled by 57.35% to $522000.0 in 2023.
  • The last three reported values for Current Deferred Revenue were $522000.0 (Q3 2023), $1.8 million (Q2 2023), and $1.2 million (Q1 2023) per Business Quant data.